The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFu Jen Catholic University Hospital

About this trial

This study seeks to compare the clinical efficacy and safety of the novel sedative Remimazolam with Dexmedetomidine in Drug-Induced Sleep Endoscopy (DISE), evaluating their performance in sedation depth stability, incidence of adverse events, and postoperative recovery time, thereby providing evidence-based guidance for sedative selection in OSA patients. Additionally, it aims to develop a model for predicting upper airway obstruction sites by analyzing Polysomnography (PSG) data with artificial intelligence, enhancing diagnostic accuracy and treatment decision-making efficiency for Obstructive Sleep Apnea (OSA) to optimize clinical management.

Eligibility criteria

Qualifiers

Patients age > 18 years old

American Society of Ansthesiologists functional class < III

Schedule to receive DISE exam for evaluation of OSAS

Disqualifiers

Patient refusal

Allergic to experimental medication

History of central nervous system diseases

History of psychiatric diseases

Trial design

Treatments tested in this trial

  • Remimazolam
  • Dexmedetomidine

Treatment groups

60 Participants
are divided into 2 treatment groups